DOCSLIB.ORG

Your Local Pharmacy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Your Local Pharmacy Your Local Pharmacy Transferring Your Prescriptions is Easy. Ask Us How Today! September 3-17 ¢ Werther’s 39 Pringles® 09 Excel 99 Original® 2 Potato Chips, 1 Selected Varieties, Caramel Hard Candies, Original, 67 g or 12 pieces 135 g Sour Cream & Onion, 68 g 999 Aveeno® Active Naturals® ® or Aveeno Baby Vicks® Eczema Care, VapoDrops, ¢ 49 99 Moisturizing Cream, Cherry Flavour 99 1 . ® 3 166 mL Sleep eze or Vitamin C, Kleenex® Nighttime Sleep Aid, Orange Drops, Go Pack, Extra Strength, 20 Drops 3 Packs, 10 Coated 10 3-Ply Caplets White Tissues Aspirin® Daily Low Dose, 81 mg, 30 Tablets Enteric Coated 99 3 Tylenol® 99 99 Gravol™ 99 Extra Strength, Adults, 500 mg, 9 7 50 mg, 3 100 Caplets Gaviscon® Taste Free Liquid or Easy to For Acid Reflux Gel Capsules, Swallow & Heartburn, 8 Capsules or 100 eZtabs Extra Strength, Quick Dissolve Fruit Blend, Chewable, 25 Chewable 8 Orange Foamtabs® Flavour Tablets 99 99 TENA® 99 8 3 Unisex 15 ® Underwear, Cottonelle ™ ® Small 14, ® RUB•A535 Salonpas FreshCare Medium 14, ® Muscle & Joint, Pain Relieving SafeFlush Technology 49 Maximum Topical Patch, Large 13 or 42 Cloths Strength Large, XLarge 11 3 or No Odour 4 Patches, Extra Strength, 13cm x 8.4cm 100 Cream 99 G.U.M® 99 99 4 Secure® 3 2 G.U.M® Denture Adhesive Cream, G.U.M® ® Zinc Free, Soft-Picks Last Up to 12 Hours, Denture Brush Original, 40 g With Travel Case, 80 Picks Penaten® Medicated 99 99 99 99 Cream, 5 8 6 7 For Common Skin Irritations, Children’s Kolik® Jamieson™ 55 g Benadryl® Original Chewable Vitamin C, Under 12 Years, Gripe Water, 500 mg, Allergy Liquid, 150 mL Liquid Bonus 100 + 20 Tablets or Bubble Gum Premium Vitamin D3, Flavour, 1,000 IU, 100 mL Bonus 200 + 40 Tablets Compare & Save! 99 Ibuprofen 99 99 99 Liquid Gel Capsules, 3 6 11 Cold 4 Extra Strength, Diarrhea Rapid Digital Medication 400 mg, Thermometer 12 Capsules Relief Extra Strength, 2 mg, Flexible Tip, Combo Pack, 30 Caplets 10 Seconds, 12 Non-Drowsy Day °C & °F & 12 Night Caplets Who Needs Supplements? Supplements aren’t for everyone, but older adults and others may need them to get the nutrients they might Supplements otherwise lack. You likely don’t need supplements if you’re a healthy adult who eats a variety of foods, including fruits, vegetables, whole grains, legumes, low-fat dairy products, lean meat, and fish. But supplements — or fortified foods — may be appropriate if you: Choosing and using supplements • Are pregnant or are trying to get pregnant If you decide to take a supplement, it’s important to: • Are age 50 or older • Have a poor appetite or have trouble getting nutritious foods • Check the label • Follow a diet that excludes entire food groups • Avoid megadoses • Have a medical condition that affects how your body digests nutrients, • Watch what you eat such as chronic diarrhea, food allergies, food intolerance, or a disease of the liver, • Tell your doctor gallbladder, intestines, or pancreas • Watch for alerts and recalls • Have had surgery on your digestive tract that affects how your body digests • Report problems nutrients 999 599 1299 Jamieson™ Redoxon® Jamieson™ Vitamin B12, Double Action, Multi 100% 1,000 mcg, Vitamin C & Zinc, Complete Vitamin, 100 Sublingual 15 Orange Adults, Tablets Effervescent Tablets 90 Caplets 1049 1199 1799 1799 2199 Flintstones™ One A DAY® Centrum® Centrum® Centrum® Active Kids Advanced Complete Select® Essentials Cardio™ Gummies, Multi-vitamin, Multivitamin/ Adults 50+, For Heart Health, With Calcium & More Vitamin D Mineral Complete Complete Extra Vitamin D, & Selenium, Supplement, Multivitamin/ Multivitamin/ 50 Gummies Women or Women or Mineral Mineral Men 50+, Men 50+, Supplement, Supplement, 90 Tablets 90 Tablets 100 Tablets 90 Tablets Did you know your local Next time you’re in our pharmacy, please feel free to speak to one of our pharmacists to find out more. Ask Your pharmacy provides a host of services for you and your • Computerized patient files • Med checks • Compounding Pharmacist family? • Compliance packaging • Clinic days • Prescription transfer from other pharmacies Benadryl® 99 99 99 Bausch 99 Bausch 99 Allergy, +Lomb +Lomb 27 6 4 9 MD 15 MD 25 mg, PreserVision PreserVision 12 Caplets Clear Bausch Eye Vitamin Eye Vitamin eyes® +Lomb and Mineral and Mineral Allergy renu® Supplement Supplement Eye Drops, Fresh™ AREDS 2 Omega-3 15 mL Multi-purpose Formula, Formula, Solution, 60 Soft Gel 120 Soft Gel 355 mL Capsules Capsules 99 99 99 99 99 4 Nix® 21 7 8 7 Dr.Scholl’s® Dermal Cream, Glaxal Base Corn Removers, For Scabies, Barriere™ Moisturizing Cream, Complex 15® DURAGEL™ 30 g Silicone Hypoallergenic, Daily Face Cream, Technology, Skin Cream, For Sensitive Hypoallergenic, 6 Medicated 100 g Skin, Oil Free, Discs 100 g 100 mL Acne Mistakes 99 Cetaphil® 99 99 People with acne might see better results if they avoid these 13 Moisturizing 19 7 common skin care mistakes: Cream ® ® • Using oily products. Instead use products that are water Cetaphil Dry to Very Dry Skin, Neutrogena based and not likely to block pores. Gentle Skin Body, Oil-free • Forgetting to wash your face daily. Problem areas need Cleanser 453 g Acne Wash, gentle cleansing with lukewarm water and mild soap. Face & Body 177 mL or 200 mL • Being too rough with your skin. 500 mL • Touching your face. Too much contact can cause flare-ups. • Picking/squeezing pimples. Can cause infections or scars. 1399 899 849 99 Glucosamine Calcium Plus Multivitamins 12 & Chondroitin Chewables & Multiminerals Multiple Vitamins or Eye Care With Ginseng, with MSM 75 Tablets + Iron Tablets 1300 mg, 50 Tablets 250 Tablets 60 Tablets Speak to your medical professional or pharmacist for more information. The material in this flyer was sourced from: www.mayoclinic.org. It is intended for information purposes only and should not be used in place of consultation with a healthcare professional. Participating retailers/pharmacies, vendors, and/or agencies are not responsible for errors, omissions, or inconsistencies with respect to the information contained in this flyer and do not accept liability whatsoever for reliance by the reader on the information contained herein. Prices in effect Friday, September 3 – Friday, September 17, 2021 or while quantities last. Flyer features and products available while supplies last. Where “assorted” and “selected” varieties are indicated, not all products may be available. We reserve the right to limit quantities due to space limitations or manufacturer supply issues. Not all items may be available as advertised. All prices are subject to applicable sales taxes. Any coupon offers will be subject to our coupon policy. Participating pharmacies are independently owned and operated. health One™ is a registered trademark of Kohl & Frisch Limited..
Load more

Recommended publications
  • Gelatina Di K-Y Da Wikipedia, L'enciclopedia Libera Salto A: Navigazione, Ricerca
    Gelatina di K-Y Da Wikipedia, l'enciclopedia libera Salto a: navigazione, ricerca /wiki/Image:K-Y.jpg/wiki/Image:K-Y.jpg /wiki/Image:K-Y.jpgUn tubo della gelatina di K-Y La gelatina di K-Y, anche conosciuta come la gelatina di Panitsa, è un lubrificante personale a base d'acqua e solubile in acqua prodotto da Johnson & Johnson. Le iniziali “K-Y„ non sono conosciute per rappresentare alcune parole - sono state descritte dal loro creatore come “lettere arbitrarie„ - ma sono mantenute per la loro marca- identità. È stato introdotto nel gennaio 1904 dal creatore Van Horn & Sawtell del suturare e farmaceutico di New York City, [1] e più successivamente acquistato da Johnson & Johnson, scopo dichiarato originale della gelatina di K-Y come lubrificante chirurgico ed è stato scelto spesso dai medici a causa della relativa base vegetale. Il prodotto ora è più ampiamente usato come lubrificante sessuale. Non reagisce con i condoms del lattice o il silicone gomma-ha basato i giocattoli del sesso. Mentre non suggerito per ingestione, ha un gusto dello sweetish, in modo da non interferire con il sesso orale. Ha una consistenza spessa e una tendenza asciugarsi durante l'uso, ma può “essere riattivato„ tramite l'aggiunta della saliva o di più acqua. La gelatina di K-Y non contiene uno spermicide. Una formulazione con nonoxynol-9 era disponibile, ma Johnson & Johnson lo ha tirato dal mercato dopo l'individuazione che potrebbe aiutare il HIV a spargersi. [2] Il prodotto può anche essere usato per gli scopi di lubrificazione quando prende la temperatura corporea dal retto.
    [Show full text]
  • Amity University
    AMITY UNIVERSITY We nurture talent --------------------UTTAR PRADESH-------------------- (Established by Ritnand Balved Education Foundation) THIS IS TO CERTIFY THAT PROJECT REPORT ENTITLED “PROBLEM IDENTIFICATION AND RECTIFICATION IN CLAIM SETTLEMENT”, IN JOHNSON & JOHNSON, NEW DELHI IS PREPARED BY DEEPAK BEHAL OF MBA (GENERAL) 3rd SEMESTER, AMITY UNIVERSITY, LUCKNOW CAMPUS, UNDER MY SUPERVISION. PLACE: LUCKNOW FACULTY GUIDE: DATE: (DR. NIMISH GUPTA) STUDENT’S CERTIFICATE Certified that this report is prepared based on the summer internship project undertaken by me in Johnson & Johnson from 4th June 2007 to 16th July 2007, under the able guidance of Mr. Ajay Rangaraj, Regional Manager, sales (north) in partial fulfilment of the requirement for award of degree of Master in Business Administration From Amity University Uttar Pradesh. Date: _____________ Signature: __________ Signature: __________ Signature: __________ Name: _____________ Name: _____________ Name: _____________ Student Faculty Guide Director ABS ACKNOWLEDGEMENT The satisfaction and Euphoria that accompany the successful completion any task would be without the mention of people who make it possible and whose constant guidance and encouragement leads all effects with success. I would like to express my sincere and profound gratitude to my project guide Dr. Nimish gupta who has been a constant source of inspiration throughout my project. I thank him for the guidance given by him to complete my project. I would also like to thank my Industry guide Mr. Ajay Rangaraj who has been of great help to me and helping me whenever I needed help. Last but not the least I would like to thank Mr. Sabharwal (ABI), Mr Harish rathuri(ABI), Mr Kashif Husain(ABI), Mr Ramesh Jaswani(ABI), Mr Suresh Nandwani(FLM), and all the staff of Johnson & Johnson who helped me in successful completion of the project without them it would have been very difficult for me to complete the project successfully.
    [Show full text]
  • Johnson & Johnson
    9/9/13 Johnson & Johnson - Wikipedia, the free encyclopedia Johnson & Johnson Coordinates: 40°29′55″N 74°26′37″W From Wikipedia, the free encyclopedia Johnson & Johnson is a U.S multinational Johnson & Johnson medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Type Public Average and the company is listed among the Fortune 500. Traded as NYSE: JNJ (http://www.nyse.com/about/listed/lcddata.html? Johnson & Johnson ranked at the top of ticker=jnj) Harris Interactive's National Corporate Dow Jones Industrial Average Component Reputation Survey for seven consecutive S&P 500 Component years up to 2005,[2] was ranked as the world's most respected company by Industry Medical equipment Barron's Magazine in 2008,[3] and was the Pharmaceutical first corporation awarded the Benjamin Founded 1886 Franklin Award for Public Diplomacy by Founder(s) Robert Wood Johnson I, the U.S. State Department in 2005 for its James Wood Johnson, funding of international education programs. Edward Mead Johnson However, in recent years the company's reputation has been adversely affected by Headquarters New Brunswick, New Jersey, United States product recalls, fines for pharmaceutical Area served Worldwide marketing practices, litigation with a group of shareholders, and other legal issues. Key people William Weldon (Chairman of the Board) Johnson & Johnson is headquartered in Alex Gorsky New Brunswick, New Jersey with the (Chief Executive Officer) consumer division being located in Products See list of Johnson & Johnson products Skillman, New Jersey. The corporation includes some 250 subsidiary companies Revenue US$ 65.030 billion (2012)[1] with operations in over 57 countries and Operating US$ 12.361 billion (2012)[1] products sold in over 175 countries.
    [Show full text]
  • Title of Each Class Name of Each Exchange on Which Registered
    1 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JANUARY 3, 1999 COMMISSION FILE NUMBER 1-3215 JOHNSON & JOHNSON (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) NEW JERSEY 22-1024240 (State of (I.R.S. Employer Incorporation) Identification No.) ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NEW JERSEY 08933 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED ------------------- ----------------------------------------- Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [ ] The aggregate market value of the voting stock held by non-affiliates of the registrant on February 23, 1999 was approximately $117.2 billion.
    [Show full text]
  • Leading from Our Strengths
    1999 ANNUAL REPORT Leading from Our Strengths Credo Values Decentralized Management Multiple Growth Platforms Global Reach Research & Development Partnering with Others Innovation Focus on the Long Term Leadership Brands Three Years in Brief–Worldwide % Change (Dollars in Millions Except Per Share Figures) 1999 1998 1997 1999 1998 Sales to customers $27,471 23,995 22,830 14.5 5.1 Net earnings* 4,167 3,003 3,311 38.8 (9.3) Cash dividends paid 1,479 1,305 1,137 13.3 14.8 Shareowners’ equity 16,213 14,077 12,866 15.2 9.4 Percent return on average shareowners’ equity* 27.5 22.3 27.4 – – Per share Net earnings – basic* $ 3.00 2.16 2.40 38.9 (10.0) – diluted* 2.94 2.12 2.34 38.7 (9.4) Cash dividends paid 1.09 0.97 0.85 12.4 14.1 Shareowners’ equity 11.67 10.13 9.26 15.1 9.5 1 7 7 Market price (year-end close) 93 /4 83 /8 64 /8 11.2 29.3 Average shares outstanding (millions) – basic 1,390.1 1,389.8 1,380.6 0.0 0.7 – diluted 1,418.2 1,417.2 1,415.4 0.1 0.1 Shareowners of record (thousands) 169.4 168.9 160.0 0.3 5.6 Number of employees (thousands) 97.8 94.3 91.1 3.7 3.5 * Net earnings and earnings per share for 1999 and 1998 include special charges of $42 million or $.03 diluted earnings per share for 1999 and $697 million or $.49 diluted earnings per share in 1998.
    [Show full text]
  • Sustainable Organization of a Lean Six Sigma Program: a Competing Values Perspective
    Georgia State University ScholarWorks @ Georgia State University Business Administration Dissertations Programs in Business Administration 8-1-2020 Sustainable Organization of a Lean Six Sigma Program: A Competing Values Perspective Marilyn J. Tom Follow this and additional works at: https://scholarworks.gsu.edu/bus_admin_diss Recommended Citation Tom, Marilyn J., "Sustainable Organization of a Lean Six Sigma Program: A Competing Values Perspective." Dissertation, Georgia State University, 2020. https://scholarworks.gsu.edu/bus_admin_diss/138 This Dissertation is brought to you for free and open access by the Programs in Business Administration at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Business Administration Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. PERMISSION TO BORROW In presenting this dissertation as a partial fulfillment of the requirements for an advanced degree from Georgia State University, I agree that the Library of the University shall make it available for inspection and circulation in accordance with its regulations governing materials of this type. I agree that permission to quote from, to copy from, or publish this dissertation may be granted by the author or, in his/her absence, the professor under whose direction it was written or, in his/her absence, by the Dean of the Robinson College of Business. Such quoting, copying, or publishing must be solely for scholarly purposes and does not involve potential financial gain. It is understood that any copying from or publication of this dissertation which involves potential gain will not be allowed without written permission of the author. Marilyn Jane Tom NOTICE TO BORROWERS All dissertations deposited in the Georgia State University Library must be used only in accordance with the stipulations prescribed by the author in the preceding statement.
    [Show full text]
  • 2002 Annual Report Three Years in Brief–Worldwide
    2002 Annual Report Three Years in Brief–Worldwide % Change (Dollars in Millions Except Per Share Figures) 2002 2001 2000 2002 2001 Sales to customers $36,298 $ 32,317 29,172 12.3 10.8 Net earnings* 6,597 5,668 4,953 16.4 14.4 Cash dividends paid 2,381 2,047 1,724 16.3 18.7 Shareholders’ equity 22,697 24,233 20,395 (6.3) 18.8 Percent return on average shareholders’ equity 28.1 25.4 26.5 – – Per Share Net earnings - basic 2.20 1.87 1.65 17.6 13.3 - diluted 2.16 1.84 1.61 17.4 14.3 Cash dividends paid 0.795 0.70 0.62 13.6 12.9 Shareholders’ equity 7.65 7.95 6.77 (3.8) 17.4 Market price (year-end close) 53.11 59.86 52.53 (11.3) 14.0 Average shares outstanding (millions) - basic 2,998.3 3,033.8 2,993.5 (1.2) 1.3 - diluted 3,054.1 3,099.3 3,099.2 (1.5) 0.0 Number of employees (thousands) 108.3 101.8 100.9 6.4 0.9 * Net earnings and earnings per share for 2002 include In-process research and development (IPR&D) charges of $189 million or .07 diluted earnings per share related to the acquisitions of Tibotec-Virco N.V. and Obtech Medical AG. Excluding the impact of these charges, 2002 net earnings increased 16.8% over 2001. Net earnings and earnings per share in 2001 and 2000 include $231 million or .07 diluted earnings per share and $45 million or .02 diluted earnings per share, respectively, related to IPR&D and ALZA merger costs in 2001 and IPR&D net of restructuring gains in 2000.
    [Show full text]
  • Neutrogena® Glow Boost Neu Ab März 2021
    Good to Glow: Neutrogena® Glow Boost Neu ab März 2021 Neuss, 1. März 2021. Der Spagat zwischen Familie, Karriere, Freunden und der nötigen Me-Time kann stressig sein, keine Frage. Das hält Frauen aber nicht davon ab, sich selbstbewusst den täglichen Herausforderungen zu stellen. Stress kann ihnen nichts anhaben – ihrer Haut allerdings schon. Sie verliert an natürlicher Strahlkraft und wirkt oft müde und fahl. Für strahlende Haut und gegen erste Zeichen der Hautalterung1 gehört Neutrogena® Glow Boost ab sofort in die Pflegeroutine jeder Powerfrau. Das Älterwerden jagt Frauen schon lange keine Angst mehr ein. Aber Hautalterung? Dafür ist es definitiv noch zu früh. Neutrogena Glow Boost ist die erste revitalisierende Gesichtspflege von Neutrogena, die die Haut strahlen lässt und gleichzeitig hilft, der Hautalterung vorzubeugen. Die Serie besteht aus Peeling, Serum, Tagespflege und LSF 30 Fluid und bildet eine abgestimmte Pflegeroutine mit wissenschaftlich bestätigten Formeln, die effektive Inhaltsstoffe enthalten. Wissenschaftliche Studien bestätigen die Effektivität der Produkte aus der Glow Boost Serie. Bis zu 96 % der Testerinnen bestätigen, dass ihre Haut nach der Verwendung gesünder aussieht und strahlender wirkt.2 Neutrogena Glow Boost - eine vollständige Pflegeroutine in nur drei Schritten für eine strahlende Haut: Das Revitalisierende Peeling mit Mandelsäure und natürlichen Peelingpartikeln reinigt und entfernt abgestorbene Hautzellen. Das Serum mit hochkonzentriertem Neoglucosamine® aktiviert den natürlichen Hauterneuerungsprozess und hilft, der Hautalterung vorzubeugen. Die Revitalisierende Tagespflege sorgt zudem für einen Extra-Frischekick. Für Schutz vor äußeren Umwelteinflüssen hilft alternativ das LSF 30 Fluid mit Vitamin C&E und UV-Schutz. Die leichte Textur und milde Formulierung der Produkte beschwert nicht und ist für alle Hauttypen geeignet – für eine geschmeidige, strahlende und gesund aussehende Haut.
    [Show full text]
  • Johnson & Johnson
    21 January 2013 GLOBAL IDEAS www.anchorcapital.co.za www.investorcampus.com Johnson & Johnson — just the right medicine Business Overview and hair care products; o.b.Tampons; Penaten and Natsuan The company is engaged in the manufacture and sale of a baby care products; PIZ Buin and Sundown sun care prod- broad range of products in the healthcare field. With over ucts; Reach toothbrushes; RoC skin care products; Shower 190 operating companies it conducts business in virtually to Shower personal care products; Splenda, a non-caloric all countries of the world. Johnson & Johnson's primary sugar substitute; Stayfree sanitary protection products; the interest, both historically and currently, has been in prod- broad family of Tylenol acetaminophen products; and Viactiv ucts related to human health and well-being. The company calcium supplements. These products are marketed princi- was organised in 1887. Its common stock is listed on the pally to the general public and distributed both to wholesal- New York Stock Exchange under the symbol JNJ and it is ers and directly to independent and chain retail outlets. headquartered in New Brunswick, New Jersey. The Pharmaceutical segment's principal worldwide fran- JNJ’s metrics are as follows: chises are in the antifungal, anti-infective, cardiovascular, dermatology, gastrointestinal, haematology, immunology, neurology, oncology, pain management, psychotropic, urol- Spot ($) 73.23 ogy and women's health fields. These products are distribut- Mkt Cap ($mn) 202,940 ed both directly and through wholesalers for use by health 12M trailing P/E 14.5 care professionals and the general public. In 2001, sales to 12M fwd P/E 13.3 three distributors, McKesson HBOC, Cardinal Distribution 10-year average P/E 16.7 and AmerisourceBergen Corp.
    [Show full text]
  • Title of Each Class Name of Each Exchange on Which Registered
    1 -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2000 COMMISSION FILE NUMBER 1-3215 JOHNSON & JOHNSON (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) NEW JERSEY 22-1024240 (State of (I.R.S. Employer Incorporation) Identification No.) ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NEW JERSEY 08933 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED ------------------- ----------------------------------------- Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [X] The aggregate market value of the voting stock held by non-affiliates of the registrant on February 27, 2001 was approximately $133.8 billion.
    [Show full text]
  • [Propuesta De Mejora Del Proceso En Un Centro De Producción De Hilo
    [Propuesta de Mejora del Proceso en un Centro de Producción de Hilo Dental] MEMORIA PRESENTADA POR: [Johanny C. Ovalles Acosta] [Máster Universitario en Ingeniería de Organización y Logística] Convocatoria de defensa: [septiembre 2018] . Resumen Este reporte de investigación a desarrollar tiene como objetivo, analizar las principales razones por las que se generan eventos de No Calidad o No Conformes (NC) en un centro de producción de la planta de manufactura Johnson & Johnson Dental Care, R.D., dicho centro se encarga de producir subensambles que forman parte del hilo dental, siendo este el producto terminado o final que se manufactura en dicha planta. A fin de poder implementar acciones correctivas y preventivas para la eliminación o disminución de los eventos de No Calidad o No Conformes, se identificaron las principales herramientas de análisis de Causa Raíz, seleccionando el Diagrama de Ishikawa o también llamado Espina de Pescado para analizar profundamente la/s causa/s potenciales que generan la situación que se presenta en dicho centro. Del mismo modo la identificación de los mayores detractores que afectan el centro de producción, luego la verificación de los procedimientos e instrucciones de trabajo vigentes de dicho centro, a fin de retarlos contra la ejecución actual del proceso, igualmente identificar los cambios necesarios a implementar con el propósito de lograr una mejor manufactura y manejo de los subensambles y por consiguiente determinar los controles de calidad y las acciones recomendables a implementar para poder optimizar el proceso de manufactura de los subensambles. Summary: The objective of this investigation report to be developed is to analyze the main reasons of the generation of Non Quality or Non Conformances (NC) in a production center of Johnson & Johnson Dental Care, R.D.
    [Show full text]
  • Creative Leadership Tim O'toole
    TIM O’TOOLE CREATIVE LEADERSHIP timotoolecreative.com • [email protected] • 212•243•0148 OBJECTIVE: Identify new leadership role leveraging agency and in-house brand expertise in design, integrated marketing, and strategy management, to create inspired, motivated, and cohesive multi-disciplinary teams, and consistently deliver strategic content and upstream innovation in a clearly defined operational framework. Portfolio available upon request. 2016 - 2019 CREATIVE DIRECTOR: CONSULTING Ongoing relationships developing Branding, Visual Identity Systems, Package Design and Graphics, Interiors, and Design Strategy for multi-industry client base. 2014 - 2016 CREATIVE DIRECTOR: JOHNSON & JOHNSON, DESIGN CAPABILITIES Management of all Consumer, Healthcare, Pharmaceutical and Corporate design activities to generate consistent people-centered design brand experiences via insight and data synthesis, category knowledge, and cultural trend scouting. Activated new organization structure, defined and implemented Integrated Marketing Communication design programs, talent acquisition and development, upstream innovation, brand identity, graphics, industrial design, package design, retail merchandising, workplace design, agency oversight, external brand partnerships, corporate sponsorship programs, and process innovation. Team Size: 35 Recognition: US patents, J&J Standard of Leadership Awards, Industry / J&J Design Awards Brands: Neutrogena (Skincare and Cosmetics), Aveeno, Clean & Clear, RoC, Korres, Le Petit Marseillais, Dabao, Piz Buin,
    [Show full text]